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apeutic approaches to treat hypertension. Great strides have
been made in the medical treatment of hypertension over the
past 50 years, but despite these advances, the number of pa-
tients with uncontrolled or treatment-resistant hypertension
remains a burgeoning problem associated with a significant
burden of resulting cardiovascular morbidity and mortality.
The advent of catheter-based approaches to effect renal
denervation, down-modulating the sympathetic nervous
system in a minimally invasive fashion, sparked tremendous
enthusiasm for physicians worldwide. The promise of
catheter-based renal denervation was one that represented a
therapeutic holy grail e a way of treating a prevalent and
morbid disease with a fix that was durable, permanent, and
not subject to medication non-adherence or patient side ef-
fects. In early studies, the data on renal denervation were
almost too good to be true, demonstrating marked and sus-
tained reductions in blood pressure with the use of a broad
range of devices and technologies.1 Yet these studies only
served to further increase expectations for the broader
dissemination of renal denervation therapies.
It was not until the completion of the SYMPLICITY HTN-3
trial, a randomized controlled trial of renal denervation with
a radiofrequency ablation catheter, that the field of renal
denervation underwent its first true reality testing. In this trial
of 535 patients with treatment-resistant hypertension ran-
domized to renal denervation with the Symplicity Flex
monopolar electrode catheter compared with a sham proce-
dure, blood pressurewas reduced in both study arms, but with* This editorial is pertaining to the article: Renal Sympathetic De
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tion compared to control.2 Since the presentation and publi-
cation of these results, a whole host of explanations for the
failure of the trial have been posited, including: variability in
patient selection and poor adherence to a stable medical
regimen, variability in measurements of blood pressure (the
primary endpoint of the trial), and variability in operator
experience and catheter technique.
While the institution of even more rigorous study pro-
cedures may be able to improve on the results of SYMPLICITY
HTN-3 by further optimizing patient selection, endpoint
ascertainment, and medication adherence, a fundamental
issue that remains problematic is whether there were poten-
tial technical problemswith the renal denervation procedures
as performed within the trial. In light of these concerns,
several novel technologies aimed at reducing the variability of
renal denervation procedures (including a further iteration of
the Symplicity catheter) are set to soon begin investigation in
trials around the world. These trials represent a real and sci-
entific attempt to resuscitate interest in a field that exhibited
great promise for the treatment of a genuinely important
public health problem.
In this light, the study by Yalagudri and colleagues in this
issue of Indian Heart Journal represents an initial attempt to
address potential limitations of the original Symplicity cath-
eter through the use of manual saline irrigation at the time of
radiofrequency ablation. By providing active surface cooling of
the electrode tip, the authors describe a method of potentially
increasing the degree of thermal injury provided by annervation Using an Externally Irrigated Radiofrequency ablation
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renal denervation seen in the SYMPLICITY HTN-3 trial relates
to an inadequacy of effective ablation.3 The use of saline
irrigation to the tip of the radiofrequency catheter in order to
effect a larger and deeper ablation lesion may be one method
of overcoming an inadequate denervation procedure. In
addition, it is an innovative solution to overcome the lack of
availability of the proprietary Symplicity generator box.
However, this approach is not without potential risks. For one,
the absence of temperature monitoring (with algorithmically
determined modulation of variable power output) may result
in creation of too deep or large an ablation lesion. Although
the authors did not describe any major adverse safety effects
with their approach, a larger sample of patients is needed
before this method can be deemed truly safe. Nonetheless, it
is laudable that the authors opted to study their novel tech-
nique and publish their results in a peer-reviewed journal,
rather than simply just applying these techniques in practice
with the backing of anecdotal evidence alone.
What next is needed in the field of renal denervation? It is
out sincere hope that the use of preclinical studies is
expanded prior to the implementation of new techniques and
technologies of denervation therapies. For example, a system
such as those proposed in the study by Yalagudri et al could
first be studied in animals in order to optimize ablation pa-
rameters while carefully monitoring safety (e.g. depth of le-
sions created). Preclinical studies serve a critical role in aiding
our understanding of how best to perform renal denervation,
and how to maximize efficacy and minimize safety concerns.
Even in themonths following the results of SYMPLICITY HTN-
3, several preclinical studies examining the location of renal
sympathetic nerves as well as the most effective ablation
strategies to treat these nerves have been presented and
published,4,5 and have already begun to inform future trials of
renal denervation therapies. Further advances in fine-tuning
optimal patient selection and in intraprocedural monitoring
of denervation efficacy are also sorely needed.
The fact that several preclinical and patient-based studies
are going ahead despite the blow that was dealt to the field
when SYMPLICITY HTN-3 was completed demonstrates howmuchpotential benefit and hope there is for a safe and durable
treatment option for patients with hypertension. Nonethe-
less, while continued perseverance is required in order to
move the field forward, there are only so many large setbacks
that can be endured before the field eventually runs out of
steam. As Yalagudri et al demonstrate, sometimes small, in-
cremental steps are required in order to regain lost
momentum.Conflicts of interest
All authors have none to declare.
Acknowledgments
Dr. Kirtane reports institutional research grants (to Columbia
University) from Medtronic Cardiovascular, Boston Scientific,
Abiomed, Abbott Vascular, Vascular Dynamics, Eli Lilly, Glaxo
Smithkline, and Astra Zeneca.r e f e r e n c e s
1. Kirtane AJ, Leon MB. The quickening path ahead for renal
denervation therapies. EuroIntervention. 2014;9:1021e1023.
2. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of
renal denervation for resistant hypertension. N Engl J Med.
2014;370:1393e1401.
3. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood
pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J.
2015;36:219e227.
4. Wilson GJ, Winsor-Hines D, Tunstall RR, et al. Bipolar multi-
electrode balloon catheter radiofrequency renal denervation
with the Vessix system: preclinical safety evaluation.
EuroIntervention. 2015;10:1239e1246.
5. Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of
sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol.
2014;64:635e643.
